# Text Description automatically generated with medium confidenceThe Prescriber e-Letter, Volume 15, Issue 3, February 2025

## Upcoming Changes to MassHealth Coverage of Rapid-Acting Insulin

MassHealth Pharmacy currently covers the authorized generic formulations of insulin lispro (Humalog®) and insulin aspart (Novolog®) without prior authorization (PA) and covers the branded formulation without PA when there is no authorized generic equivalent (i.e., Humalog® [insulin lispro] 100 units/mL cartridge; Humalog® [insulin lispro] 200 units/mL).

Effective April 1, 2025, insulin aspart (Novolog®) will require PA

Effective April 1, 2025, PA will be required for all MassHealth members prescribed insulin aspart (Novolog®) to encourage the use of the cost-effective short-acting insulin agents. If clinically appropriate, please consider transitioning your members to insulin lispro (Humalog®), which will remain available without PA. If transition to insulin lispro (Humalog®) would not be clinically appropriate, you must submit a PA for insulin aspart (Novolog®) to MassHealth. The PA clinical criteria will require documentation of an appropriate diagnosis and inadequate response, adverse reaction, or contraindication to insulin lispro (Humalog®) (e.g., inadequate blood glucose control, documented intolerance or hypersensitivity, FDA-labeled contraindication, etc.).

## Summary of PA Status of Rapid-Acting Insulin Products

|  |
| --- |
| Available without PA |
| * Humalog® (insulin lispro) 100 units/mL cartridge, 200 units/mL * insulin lispro 100 units/mL prefilled syringe, vial |
| PA Required |
| * Admelog® (insulin lispro) * Apidra® (insulin glulisine) * Afrezza® (insulin human inhalation powder) * Humalog® (insulin lispro) 100 units/mL prefilled syringe, vial * Humalog Tempo® (insulin lispro) * Fiasp® (insulin aspart) * insulin aspart * Lyumjev® (insulin lispro-aabc) * Lyumjev Tempo® (insulin lispro-aabc) * Novolog® (insulin aspart) |

The MassHealth Drug List, including [Therapeutic Class Table 26](https://mhdl.pharmacy.services.conduent.com/MHDL/pubtheradetail.do?id=26) (outlining the coverage status and PA criteria for antidiabetic agents) and the [Antidiabetic Agents PA form](https://mhdl.pharmacy.services.conduent.com/MHDL/pubdownloadpa.do?id=9491), will be updated to reflect these changes. Additional information can be found on the [MassHealth Drug List](https://mhdl.pharmacy.services.conduent.com/MHDL/pubintro.do?category=Introduction+to+MassHealth+Drug+List).

The Prescriber e-Letter is an update designed to enhance the transparency and efficiency of the MassHealth drug prior-authorization (PA) process and the MassHealth Drug List. Each issue highlights key clinical information and updates to the MassHealth Drug List. The Prescriber E-Letter was prepared by the MassHealth Drug Utilization Review Program and the MassHealth Pharmacy Program.